Published on Thursday October 06, 2022

We are working on the following new projects:

  • We signed a contract for medical writing activities with Fabomotizole.

We are happy to reach the following milestones in our projects:

  • 5 sites were opened in the Adezmapimod + Vimdemer trial in adhesions during surgeries.
  • All subjects’ visits were completed in the Nimesulide trial. The site audit was performed.
  • 3 sites were opened in the Fabomotizole trial in adaptation disorders.
  • The first subject was randomized in India in the international phase III clinical trial of the original drug for the patients with chronic myeloid leukemia. The 14 sites of 25 were opened.